Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis.

Trial Profile

Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2012

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Pseudomonal infections; Respiratory tract infections
  • Focus Therapeutic Use
  • Acronyms ELITE
  • Sponsors Novartis
  • Most Recent Events

    • 06 Jan 2010 Planned end date (30 Sep 2007) added as reported by Netherlands Trial Register record.
    • 16 Dec 2009 Results were presented in Thorax.
    • 13 Dec 2009 New source identified and integrated (ISRCTN: Current Controlled Trials record).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top